Pharma News

What is the current valuation of BrainStorm Cell Therapeutics’s NurOwn

NurOwn is a cell therapy commercialized by BrainStorm Cell Therapeutics, with a leading Phase III program in Amyotrophic Lateral Sclerosis. According to Globaldata, it is involved in 8 clinical trials, of which 6 were completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of NurOwn’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for NurOwn is expected to reach an annual total of $273 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

NurOwn Overview

Debamestrocel (NurOwn) is under development for the treatment of neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (primary and secondary sclerosis), Parkinson’s disease (PD), Huntington’s disease, peripheral nerve injury, Coronavirus Disease 2019 (COVID-19), acute respiratory distress syndrome and autism spectrum disorder. The therapy is administered by intramuscular and intrathecal routes. NurOwn is an autologous, adult stem cell therapy developed based on a differentiation method which reprograms bone marrow-derived mesenchymal stem cells (MSC) into highly specialized, neuron-supporting cells. It is developed based on NurOwn cell therapy platform.

BrainStorm Cell Therapeutics Overview

BrainStorm Cell Therapeutics, formerly Golden Hand Resources Inc, is a biotechnology company which develops autologous stem cell therapies for neurodegenerative diseases. Its pipeline mesenchymal stem cell products are being developed based on cell therapy platform NurOwn, customized for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, parkinson’s disease, huntington’s disease, autism spectrum disorder, peripheral nerve injury and other indications. Its proprietary technology NurOwn induces mesenchymal stem cells to secrete high levels of neurotrophic factors to promote the survival of neurons. The company has operations in the US and Israel. BrainStorm Cell Therapeutics is headquartered in New York, the US.

The operating loss of the company was US$24.5 million in FY2021, compared to an operating loss of US$31.7 million in FY2020. The net loss of the company was US$24.5 million in FY2021, compared to a net loss of US$31.8 million in FY2020.

For a complete picture of NurOwn’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

Source link
#current #valuation #BrainStorm #Cell #Therapeuticss #NurOwn

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *